New Consortium aims to Standardize and Accelerate Development of Advanced Therapy Medicinal Products in €25.5 million project

Accelerating Research and Innovation for Advanced Therapies (ARDAT), a new, five-year European consortium supported by the Innovative Medicines Initiative (IMI), announced on November 23rd its launch. The precompetitive consortium brings together the leading expertise of 34 academic, nonprofit and private organizations, led by Pfizer (ARDAT Project Lead: Dr Gregory LaRosa) and the University Of Sheffield (ARDAT Coordinator: Professor Mimoun Azzouz), and experts from across Europe and the US with the shared goal of helping to standardize and accelerate development of Advanced Therapy Medicinal Products (ATMPs) and potentially helping to bring these transformative treatments to patients sooner. The field of ATMP research, which includes gene and cell therapies, is expected to grow exponentially in the coming years, with potentially up to 10-20 new drug applications submitted per year to the FDA by 2025. The ARDAT consortium will aim to bring together researchers from public and private organizations to help fill the knowledge gaps in how these therapies could potentially work, and to develop appropriate standards to aid researchers, developers and regulators in accelerating effective and safe gene and cell therapies to benefit patients.

For further information, see Accelerating Research and Innovation for Advanced Therapies (http://ardat.org/new-consortium-aims-to-standardize-and-accelerate-development-of-advanced-therapy-medicinal-products-in-e25-5-million-project-2/?utm_source=The+Cell+%2B+Gene+Curator&utm_campaign=9d9f88a7cf-EMAIL_CAMPAIGN_2020_03_13_07_59_COPY_01&utm_medium=email&utm_term=0_7afca2f88c-9d9f88a7cf-372768521)

Leave a Reply

Your email address will not be published. Required fields are marked *